Brian Dymock

Brian leads the chemistry and biology groups at QEDDI working on small molecule preclinical drug discovery. Previously, Brian worked in discovery research and development in large pharmaceutical companies, biotech and academia.

He was Associate Professor in Medicinal Chemistry at the National University of Singapore and previously Head of Chemistry for SBIO Pte Ltd in Singapore, where his team was responsible for the discovery of Pacritinib, Pracinostat, TG02, VS-5584 and two other clinical candidates. Pacritinib was approved by the FDA in 2022 for myelofibrosis patients with low platelets.

Brian led the chemistry team at Vernalis which discovered Luminespib in collaboration with the Institute of Cancer Research. Brian has also been a Department Manager at Evotec and a Team Leader at Roche UK. He earned his PhD in organic chemistry from the University of Glasgow. Brian has served as an Editorial Advisory Board Member for the Journal of Medicinal Chemistry since 2020.

Research Interest

• Fragment screening using Surface Plasmon Resonance (SPR) and Weak Affinity Chromatography (WAC)
• Hydrogen sulfide donor compounds as cardiovascular and anticancer agents
• Designed Multiple Ligands (e.g. HDAC-HSP90, HDAC-JAK combination drugs)
• Novel inhibitors of Histone Methyl Transferases (HMTs)
• Novel inhibitors of kinesin enzymes
• Targeting p53 modulators to cancer cells
• Selective Inhibitors of mTOR kinase